DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
July 23rd 2024In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.
Read More
Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
July 23rd 2024In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.
Read More
Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.
Read More
Examining the use of PD-L1 and tTMB in the CASPIAN Trial
Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.
Read More
Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
Medical experts specializing in small cell lung cancer (SCLC) delve into the complex topic of immunotherapy resistance, exploring potential mechanisms, clinical implications, and potential strategies to overcome this challenge in the treatment of patients with SCLC.
Read More
Predictors of Immunotherapy Response in Limited and Extensive SCLC
Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.
Read More
Examining 3-Year Update Data from the CASPIAN Trial
A medical expert discusses the impact of the 3-year overall survival data from the CASPIAN trial on the treatment landscape for extensive-stage small cell lung cancer (ES-SCLC), emphasizing the significance of the long-term follow-up results in shaping the current treatment paradigm.
Read More
cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.
Read More
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
Panel experts analyze findings from the phase 3 ADRIATIC trial, examining overall and progression-free survival data, exploring the interaction between durvalumab and concurrent chemoradiotherapy within the tumor microenvironment, and evaluating the impact of time intervals from the completion of concurrent chemoradiotherapy to the initiation of consolidation therapy with a PD-L1 inhibitor.
Read More
Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.
Read More
Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.
Read More
Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.
Read More
Major Adverse Events of Anti-HER2 Therapies
Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.
Read More
HER2-Targeted Therapies in NSCLC
Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.
Read More
Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.
Read More
Testing Patients with NSCLC for HER2 Mutations
Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.
Read More